Cellular therapy in older adults with relapsed/refractory diffuse large B-cell lymphoma.

IF 3.5 3区医学 Q2 ONCOLOGY

Frontiers in Oncology Pub Date : 2024-10-22 eCollection Date: 2024-01-01 DOI:10.3389/fonc.2024.1481950

Naseem Esteghamat, Aaron Tsumura, Gabriel Marquez-Arreguin, Joseph Tuscano

{"title":"Cellular therapy in older adults with relapsed/refractory diffuse large B-cell lymphoma.","authors":"Naseem Esteghamat, Aaron Tsumura, Gabriel Marquez-Arreguin, Joseph Tuscano","doi":"10.3389/fonc.2024.1481950","DOIUrl":null,"url":null,"abstract":"<p><p>Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is an aggressive disease with poor prognosis and limited therapeutic options. High-dose chemotherapy with autologous hematopoietic stem cell transplantation (autoHCT) was historically the curative-intent treatment for patients who demonstrated chemosensitivity to salvage therapy. However, a significant portion of patients do not make it autoHCT due to disease progression or overall fitness and eligibility. This is of particular concern in the older adult population. In recent years, significant advances in cellular therapies including chimeric antigen receptor (CAR) T-cells and bispecific antibodies, in addition to improvement in autoHCT tolerability, have allowed for additional treatment options for patients with R/R DLBCL. These novel therapies offer the potential for durable remissions and cure, and should be considered in older patients. We present a review focused on the safety and efficacy of cellular therapies in the older adult population with R/R DLBCL.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534736/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fonc.2024.1481950","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is an aggressive disease with poor prognosis and limited therapeutic options. High-dose chemotherapy with autologous hematopoietic stem cell transplantation (autoHCT) was historically the curative-intent treatment for patients who demonstrated chemosensitivity to salvage therapy. However, a significant portion of patients do not make it autoHCT due to disease progression or overall fitness and eligibility. This is of particular concern in the older adult population. In recent years, significant advances in cellular therapies including chimeric antigen receptor (CAR) T-cells and bispecific antibodies, in addition to improvement in autoHCT tolerability, have allowed for additional treatment options for patients with R/R DLBCL. These novel therapies offer the potential for durable remissions and cure, and should be considered in older patients. We present a review focused on the safety and efficacy of cellular therapies in the older adult population with R/R DLBCL.

查看原文本刊更多论文

复发/难治性弥漫大 B 细胞淋巴瘤老年患者的细胞疗法。

复发/难治（R/R）弥漫大B细胞淋巴瘤（DLBCL）是一种侵袭性疾病，预后差，治疗方案有限。大剂量化疗联合自体造血干细胞移植（autoHCT）历来是对抢救治疗化疗敏感的患者的根治性治疗方法。然而，有相当一部分患者由于疾病进展或总体健康状况和资格问题而无法进行自体造血干细胞移植。这在老年人群中尤其令人担忧。近年来，包括嵌合抗原受体（CAR）T 细胞和双特异性抗体在内的细胞疗法取得了重大进展，此外，自体血细胞移植的耐受性也得到了改善，这为 R/R DLBCL 患者提供了更多的治疗选择。这些新型疗法具有持久缓解和治愈的潜力，老年患者应考虑使用。我们将对细胞疗法在R/R DLBCL老年患者中的安全性和有效性进行综述。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

6.20

自引率

10.60%

发文量

6641

审稿时长

14 weeks

期刊介绍： Cancer Imaging and Diagnosis is dedicated to the publication of results from clinical and research studies applied to cancer diagnosis and treatment. The section aims to publish studies from the entire field of cancer imaging: results from routine use of clinical imaging in both radiology and nuclear medicine, results from clinical trials, experimental molecular imaging in humans and small animals, research on new contrast agents in CT, MRI, ultrasound, publication of new technical applications and processing algorithms to improve the standardization of quantitative imaging and image guided interventions for the diagnosis and treatment of cancer.